抗HER-2靶向治疗乳腺癌在研临床试验进展

摘要

目前抗人表皮生长因子受体2(human epidermal growth factor receptor-2,HER-2)阳性乳腺癌临床研究关注不同机制下靶向药物的联合、靶向药物与内分泌治疗联合、双靶向药物与化疗药物联合,目的是为未来抗HER-2临床治疗指明方向.本文着重介绍国内外在研的Ⅱ~Ⅲ期临床试验,同时介绍有较好应用潜能的靶向药物,主要包括新型小分子靶向药物、单克隆抗体靶向药物、单克隆抗体偶联物、双靶点药物联合治疗、靶向药物联合内分泌治疗、靶向联合化疗、曲妥珠单抗皮下注射制剂、HER-2肿瘤疫苗等.%For HER-2 positive breast cancer, HER-2-targeted agents combined with agents that target downstream signaling or alternative pathways, and endocrine therapy has been investigated in clinical settings. This paper focuses on studies involving phaseⅡand phaseⅢclinical trials for new targets with enhanced clinical applications, including novel small molecular targeting agents, monoclonal antibody-targeted drugs, monoclonal antibody conjugates, dual target drug combination therapy, drug targeting combined with endocrine and targeted chemotherapies, trastuzumab subcutaneous injection, and HER-2 tumor vaccine.